Btk, Bruton tyrosine kinase, (S) Sunvozertinib, (S)-DZD9008, (S)Sunvozertinib, (S)-Sunvozertinib, DZD 9008, DZD9008, DZD-9008, breast cancer, Epidermal growth factor receptor, ErbB-1, EGFR, HER2, HER1, Her2, Inhibitor, mutant forms of ErbB, inhibit, lung, N-[5-[[4-[5-Chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide, Sunvozertinib
(S)-Sunvozertinib (DZD9008) is an irreversible, selective inhibitor targeting EGFR and HER2 tyrosine kinases. It is a research tool for investigating oncogenic mutations in preclinical models, demonstrating activity in both cellular assays and in vivo studies against EGFR-mutant cancers, including those with exon 20 insertions.
